CSL stock loses 0.17 percent pre-market to EUR 112.40
Published on 10/08/2026 at 08:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CSL stock was at EUR 112.40 pre-market at Lang & Schwarz at 8:33 a.m. CEST on October 8, 2026. That was minus 0.17 percent versus the EUR 112.59 prior close at Lang & Schwarz on October 7, 2026.
Pre-market trading
Lang & Schwarz showed a bid of EUR 111.58 and an ask of EUR 113.22 for CSL at the stated time. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of CSL stock.
Recent company announcement
On October 4, 2026, CSL’s newsroom listed a global partnership with Alentis Therapeutics to develop and commercialize lixudebart for rare kidney and liver diseases. The announcement said Alentis would receive an initial payment of US$355 million and could receive up to US$1.2 billion in commercial milestones. It also said global profits would be shared. CSL’s newsroom identified the item as company news.
Investor information
CSL’s investor page says the company has announced its 2026 full-year financial results for the period ending June 30, 2026. The page states that the associated webcast was broadcast on August 18, 2026, and provides access to the annual report. It also lists CSL’s 2026 annual general meeting for October 27, 2026. CSL’s investor page contains the financial-results and meeting information.
